Whole‐Blood RNA Expression of Immunosuppressive Cell‐Related Genes Is Associated With Prostate Cancer Progression
International Journal of Urology · 2026
DOI: 10.1111/iju.70323 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, 2026. Verfasst von Yoshiki Koketsu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objectives
Progression to castration‐resistant prostate cancer is influenced by immunosuppressive cells. Whole blood RNA profiling targeting these cells offers a minimally invasive method for prognostication and treatment stratification.
Methods
Patients scheduled to undergo prostate biopsy at Kanazawa University Hospital between July 2019 and April 2023 were prospectively enrolled. Whole blood samples were collected at the time of biopsy, and time to castration‐resistant prostate cancer was analyzed based on immunosuppressive cell‐related gene expression patterns.
Results
Among the 400 patients who underwent prostate biopsy, 176 prostate cancer cases and 97 non‐malignant cases were analyzed. Of the prostate cancer cases, 43 (24%) had metastatic disease. In prostate cancer patients, whole blood expression of CCR2, CCL5, CCR4, and FOXP3 was significantly elevated in metastatic cases and associated with a shorter time to castration‐resistant prostate cancer. Based on the number of highly expressed genes, patients were stratified into poor (3–4 genes), intermediate (1–2 genes), and favorable (0 genes) risk groups. This classification revealed distinct progression rates, with 2‐year castration‐resistant prostate cancer‐free survival rates of 74%, 84%, and 92% for the poor, intermediate, and favorable groups, respectively. Among metastatic patients, CCR2 was the only gene that remained significantly associated with earlier progression to castration‐resistant prostate cancer ( p = 0.0038).
Conclusions
Immune‐related gene expression in peripheral blood may serve as a minimally invasive prognostic biomarker for prostate cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
- Department of Clinical Engineering, Faculty of Health Sciences, Komatsu University, Komatsu, Japan.
ORCID-Profile: Hiroaki Iwamoto, Tomohiro Hori, Ryunosuke Nakagawa, Hiroshi Kano, Tomoyuki Makino, Renato Naito, Hiroshi Yaegashi, Kazuyoshi Shigehara, Takahiro Nohara
Zitieren
APA
Koketsu, Y., Iwamoto, H., Hiratsuka, K., Inaba, T., Hori, T., Nakagawa, R., Toriumi, R., Aoyama, S., Kamijima, T., Kano, H., Makino, T., Naito, R., Kadomoto, S., Yaegashi, H., Shigehara, K., Nohara, T., Nakata, H., Izumi, K., & Mizokami, A. (2026). Whole‐Blood RNA Expression of Immunosuppressive Cell‐Related Genes Is Associated With Prostate Cancer Progression. International Journal of Urology. https://doi.org/10.1111/iju.70323
Vancouver
Koketsu Y, Iwamoto H, Hiratsuka K, Inaba T, Hori T, Nakagawa R, et al. Whole‐Blood RNA Expression of Immunosuppressive Cell‐Related Genes Is Associated With Prostate Cancer Progression. International Journal of Urology. 2026. doi:10.1111/iju.70323
BibTeX
@article{Koketsu2026,
author = {Koketsu, Yoshiki and Iwamoto, Hiroaki and Hiratsuka, Kaoru and Inaba, Takahiro and Hori, Tomohiro and Nakagawa, Ryunosuke and Toriumi, Ren and Aoyama, Shuhei and Kamijima, Taiki and Kano, Hiroshi and Makino, Tomoyuki and Naito, Renato and Kadomoto, Suguru and Yaegashi, Hiroshi and Shigehara, Kazuyoshi and Nohara, Takahiro and Nakata, Hiroki and Izumi, Kouji and Mizokami, Atsushi},
title = {Whole‐Blood RNA Expression of Immunosuppressive Cell‐Related Genes Is Associated With Prostate Cancer Progression},
journal = {International Journal of Urology},
year = {2026},
doi = {10.1111/iju.70323}
}
EUVIMED